Angelo Camporeale

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

Vladimir Skljarevski, Tina M. Oakes, Qi Zhang et al. · JAMA Neurology · 2017 · 174 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Angelo Camporeale, David Kudrow, Ryan Sides et al. · BMC Neurology · 2018 · 141 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study

Tina M. Oakes, Vladimir Skljarevski, Qi Zhang et al. · Cephalalgia · 2018 · 50 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies

Tina M. Oakes, Richard J. Kovacs, Noah Rosen et al. · Headache The Journal of Head and Face Pain · 2019 · 47 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study

Himanshu P. Upadhyaya, Josep Antoni Ramos‐Quiroga, Lenard A. Adler et al. · The European Journal of Psychiatry · 2013 · 30 citations · Full text

Medicine, Pharmacotherapy, Psychiatry +14